Managers

Eduardo Saverin's VC firm B Capital racks up over $406 mln for sophomore fund

B Capital, a venture firm co-founded by Facebook co-founder Eduardo Saverin, has raised over $406 million for its second fund, according to an SEC filing. No target was listed in the document. With offices in Los Angeles, San Francisco, Singapore and New York, B Capital invests in tech companies.

Alexei Andreev of Lyft backer AutoTech on the changing world of mobility

Enlitic scores $15 mln Series B

San Francisco-based Enlitic, a medical startup, has secured $15 million in Series B funding. Marubeni led the round with participation from other investors that included Capitol Health.

Data Spotlight: Sequoia, NEA, GV top list of most active VCs in Q1

Following the largest quarter in history, SoftBank-led deals give lift to Q1 investing

Gene editing startup Inscripta pulls in $20 mln

Boulder, Colorado-based Inscripta, a gene-editing startup, has raised $20 million in funding. The investors were Venrock, Foresite, Mérieux Développement, Paladin Capital Group, MLS Capital and NanoDimension.

Giblib takes in $2.5 mln seed

Giblib, a streaming media platform offering on-demand medical lectures and surgical videos, has raised $2.5 million in seed funding. The investors included Mayo Clinic, Venture Reality Fund, Wavemaker 360, USC Marshall Venture Fund and Michelson 20MM.

HealthVerity fetches $25 mln Series C

HealthVerity Inc, a foundation for the rapid creation, exchange and management of healthcare and consumer data, has secured $25 million in Series C funding. Foresite Capital led the round with participation from other investors that included Flare Capital Partners and Greycroft Partners.

Biotech firm Dyne Therapeutics nabs $50 mln Series A

Cambridge, Massachusetts-based Dyne Therapeutics, a new biotechnology company, has secured $50 million in Series A funding. The investors were Atlas Venture, Forbion and MPM Capital.

Nauta Capital wraps up new fund

Nauta Capital, a pan-European venture firm, has closed its new fund at 55 million euros. The Sidecar Fund will invest in early-stage tech companies. The fund's investors include British Patient Capital, the European Investment Fund, the ICF and the ICO.